Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina

Cancer Epidemiology

Volumn 38, Issue 5, 2014, Pages 504-510

  Iljazović, Ermina ^a   Mena, Marisa ^b   Tous, Sara ^b   Alemany, Laia ^b,c   Omeragić, Feda ^d   Sadiković, Azra ^a   Clavero, Omar ^b   Vergara, Marleny ^b   Bosch, F Xavier ^b   de Sanjosé, Silvia ^b,c  

^a UNIVERSITY CLINICAL CENTER TUZLA   (Bosnia and Herzegovina)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d Gynecology and Obstetrics Clinic Omeragi   (Bosnia and Herzegovina)

Author keywords

Bosnia and Herzegovina; Cervical cancer; HPV types; Vaccines

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; BOSNIA AND HERZEGOVINA; CANCER CONTROL; CANCER PREVENTION; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; UTERINE CERVIX CANCER; WART VIRUS; AGE DISTRIBUTION; CARCINOMA, SQUAMOUS CELL; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; AGE DISTRIBUTION; BOSNIA-HERZEGOVINA; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84908106830     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.06.004     Document Type: Article

References (28)

1. Arbyn M., Castellsagué X., de Sanjosé S., Bruni L., Saraiya M., Bray F., et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22:2675-2686.
2. Arbyn M., Raifu A.O., Weiderpass E., Bray F., Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009, 45:2640-2648.
3. Bray F., Loos A.H., McCarron P., Weiderpass E., Arbyn M., Møller H., et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005, 14:677-686.
4. Arbyn M., Antoine J., Magi M., Smailyte G., Stengrevics A., Suteu O., et al. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer 2011, 128:1899-1907.
5. Bray F., Lortet-Tieulent J., Znaor A., Brotons M., Poljak M., Arbyn M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine 2013, 31S:H32-H45.
6. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2013, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr [accessed 10.06.14].
7. Poljak M., Seme K., Maver P.J., Kocjan B.J., Cuschieri K.S., Rogovskaya S.I., et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine 2013, 31S:H59-H70.
8. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
9. Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012, 30(S5):F88-F99.
10. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(S5):F123-F138.
11. Iljazović E., Mustadenagić-Mujanović J., Karasalihović Z., Cickusić E., Avdić S. Presence of high risk human-papillomavirus (HPV) in the low grade cervical lesion. Med Arh 2006, 60(1):30-32.
12. Merk&Co.Inc. Annual report 2012, Available at: http://www.merck.com/investors/financials/form-10-k-2012.pdf [accessed 10.06.14].
13. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
14. Kleter B., van Door L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999, 37(8):2508-2517.
15. Geraets D., Alemany L., Guimera N., de Sanjose S., de Koning M., Molijn A., et al. Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol 2012, June. 10.1002/path.4065.
16. Insinga R.P., Liaw K.L., Johnson L.G., Madeleine M.M. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008, 17(7):1611-1622.
17. Wentzensen N., Schiffman M., Dunn T., Zuna R.E., Gold M.A., Allen R.A., et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009, 125(9):2151-2158.
18. Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4 year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
19. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non vaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
20. Alemany L., Pérez C., Tous S., Llombart-Bosch A., Lloveras B., Lerma E., et al. Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. Gynecol. Oncol. 2012, 124:512-517.
21. Mariani L., Monfulleda N., Alemany L., Vizza E., Marandino F., Vocaturo A., et al. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer 2010, 10:259-266.
22. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128(4):927-935.
23. Jancar N., Kocjan B.J., Poljak M., Lunar M.M., Bokal E.V. Distribution of human papillomavirus genotypes in women with cervical cancer in Slovenia. Eur J Obstet Gynecol Reprod Biol 2009, 145:184-188.
24. Malisic E., Jankovic R., Jakovljevic K., Cavic M. Abstracts of the 4th international congress of molecular medicine. In Vivo 2011, 25:467.
25. Hadzisejdic I., Simat M., Bosak A., Krasević M., Grahovac B. Prevalence of human papillomavirus genotypes in cervical cancer and precursor lesions. Coll Antropol 2006, 30(4):879-883.
26. Vaccarella S., Franceschi S., Snijder P.J., Herrero R., Meijer C.J., Plummer M., et al. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2010, 19:503-510.
27. Joura E. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women. Abstracts of the EUROGIN 2013 congress.
28. Serrano B., Alemany L., Tous S., Bruni L., Clifford G.M., Weiss T., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012, 7(1):38.